Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2020 | TOURMALINE-AL1: ixazomib and dexamethasone for AL amyloidosis

Giampaolo Merlini • 24 Sep 2020
ISA 2020
Amyloidosis Rare Diseases Dexamethasone Ixazomib
TOURMALINE-AL1

Giampaolo Merlini, MD, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, discusses the Phase III TOURMALINE-AL1 trial (NCT01659658), a study that compares the efficacy of ixazomib and dexamethasone versus physician’s choice in relapsed or refractory systemic light-chain (AL) amyloidosis patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Giampaolo Merlini

2:18
The potential of CAR-T therapy for the treatment of amyloidosis
Giampaolo Merlini • 10 May 2022
5:57
Treatment approaches for amyloidosis patients with advanced cardiac involvement
Giampaolo Merlini • 10 May 2022
3:23
Novel agents and clinical trials emerging for the treatment of AL amyloidosis
Giampaolo Merlini • 10 May 2022
3:33
Advances in AL amyloidosis
Giampaolo Merlini • 10 May 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals